JZL195

JZL195 occupies a distinctive niche in cannabinoid pharmacology because it is the standard tool for reproducing the full behavioural profile of direct CB1 agonists such as delta-9-tetrahydrocannabinol (THC) without administering an exogenous cannabinoid. Whereas selective FAAH inhibitors (for example URB597 and PF-3845) raise only anandamide, and selective MAGL inhibitors (for example JZL184) raise only 2-AG, neither single-enzyme blockade recreates the complete THC-like syndrome. JZL195 elevates both endocannabinoids at once and, in doing so, produces additive, CB1-mediated effects that neither inhibitor achieves alone ^[1][2].

In the mouse tetrad test, the classical screen for CB1 agonism, JZL195 produces analgesia, hypomotility and catalepsy, and it fully substitutes for THC in drug-discrimination assays; both effects are reversed by CB1 antagonists such as rimonabant ^[1][2]. This has made JZL195 valuable for mapping which endocannabinoid-regulated behaviours depend on one pathway, the other, or a crosstalk between the two. In analgesia research it has attracted particular interest because dual blockade produces greater anti-allodynic efficacy than single-enzyme inhibition while retaining a wider therapeutic window than direct receptor agonists in some pain models ^[3][4][5].

It remains strictly a preclinical laboratory reagent. There is no established human dosing, no clinical development programme, and the very completeness of its cannabimimetic profile (the property that makes it scientifically useful) also raises the tolerance, dependence and psychoactive concerns associated with full CB1 activation ^[1][2].

JZL195 is a research chemical for laboratory use only (research use only, RUO). It has not been tested for safety in humans, has no approved therapeutic indication, and must not be self-administered. All available data come from cell-free enzyme assays and rodent studies. The practical caution that follows from its mechanism is that, unlike single-enzyme inhibitors, dual FAAH/MAGL blockade reproduces the full spectrum of CB1 activation, so the same profile that makes it scientifically useful (catalepsy, sedation, hypomotility, motor incoordination and THC-like subjective effects in animals) also carries the psychoactive, tolerance and dependence liabilities associated with direct cannabinoid agonism ^[1][2][5].

Sustained maximal 2-AG elevation in particular has been linked in the broader MAGL literature to CB1 receptor downregulation and functional tolerance. As with other carbamate serine-hydrolase inhibitors, off-target activity against other hydrolases is possible and should be controlled for. It should be handled only by trained personnel under appropriate institutional and legal oversight.

JZL195 was developed in the laboratory of Benjamin Cravatt at The Scripps Research Institute and first described in a 2009 Proceedings of the National Academy of Sciences paper led by Jonathan Z. Long, with pharmacology and behavioural work carried out in collaboration with Aron Lichtman and colleagues ^[1]. It emerged directly from the same medicinal-chemistry program that produced the selective MAGL inhibitor JZL184, and was designed as a deliberately non-selective (dual) probe to answer why neither FAAH nor MAGL blockade alone reproduces the effects of THC. It has since become a widely cited pharmacological tool for studying endocannabinoid crosstalk.

Within cannabinoid neuroscience, JZL195 is well regarded as a clean, potent and reliable tool for driving combined AEA and 2-AG signalling and for benchmarking the full cannabimimetic profile against selective FAAH or MAGL inhibitors. It is valued specifically because it lets researchers separate behaviours governed by a single endocannabinoid pathway from those requiring both, and it features frequently in analgesia and drug-discrimination studies. It is not a consumer compound and has no reputation as a supplement or medicine; its standing is entirely as a research reagent.